Combining Aplidin (plitidepsin) with dexamethasone significantly extends their survival in heavily pretreated multiple myeloma patients compared to dexamethasone alone, data from a Phase 3 trial show. PharmaMar, Aplidin’s maker, presented these findings in an oral presentation at the recent 2018 American Society of Clinical Oncology (ASCO) Annual Meeting  in Chicago. …
A combination of Pomalyst (pomalidomide) and low-dose dexamethasone is cheaper than either Darzalex (daratumumab) or Kyprolis (carfilzomib) alone as a treatment for relapsed or refractory multiple myeloma (RRMM), a study shows. The research, published in Clinical Therapeutics, is titled “Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the…
A new study reports that the specific type of multiple myeloma (MM) may affect how long the drug Darzalex (daratumumab) remains in circulation, affecting its effectiveness for the treatment and management of the disease. Results from the study, “Influence of Disease and Patient Characteristics on Daratumumab Exposure…
Relapsed multiple myeloma patients who receive Kyprolis (carfilzomib) plus dexamethasone as their second-to-fourth treatment regimen survive a median of 7.6 months longer than those given Velcade (bortezomib) and dexamethasone, new data from the ENDEAVOR trial (NCT01568866) has shown. In a head-to-head comparison, the ENDEAVOR study is the…
Get regular updates to your inbox.